Bayer, Epitomics enter service agreement for antibody technology

NewsGuard 100/100 Score
May 27 2011

Epitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody technology to produce antibodies for Bayer HealthCare's drug target identification and validation.

"Epitomics has had a long-standing experience with Bayer HealthCare. This new agreement is a major expansion of our collaboration and confirms the success of our premium technology platform," said Guo-Liang Yu, PhD, CEO of Epitomics, Inc.

"Our recent experience with the Epitomics rabbit antibody technology has been impressive and we are very pleased to be expanding our collaboration with Epitomics," said Clive R. Wood, Ph.D., Senior VP and Head of Global Biologics, Bayer HealthCare.

SOURCE Epitomics, Inc.

Posted in: Device / Technology News | Medical Science News

Tags: , , , , ,

Comments (0)

Suggested Reading

Broad-spectrum neutralizing antibody mAb-39 targets conserved S2 epitope in SARS-CoV-2
Single dose of malaria monoclonal antibody 77% effective in children, trial in Mali shows
Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression
Study reveals why COVID-19 antibodies fade quickly
Antibody discovery could explain mysteries about COVID-19 and long COVID
Study shows potential for universal flu vaccine with broad antibody response
Study: Antibody combination shows safety and anti-tumor activity in advanced cancer patients
Structural study identifies target for broad-spectrum antivirals against herpesviruses

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New monoclonal antibody vaccine slashes malaria risk in children